Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income ...